Follow the Ajanta Pharma share price and the full directors' dealings record of the company, a listed equity based in India. Shares trade on the IN market, under the supervision of SEBI (PIT + SAST). Market capitalisation: €444.1bn. The latest transaction was disclosed on 28 August 2026 (Pledge). Among the most active insiders: Ravi P Agrawal, trustee Ravi Agrawal Trust. All data is free.
16
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€93m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ajanta Pharma Buy (bullish), based on 12 analysts. Average price target: ₹3,207.58.
22Σ signal
Buys n/a€93m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,195 of 29,063 companies
60.6
score / 100
Value
34
Quality
88
FCF yld0.4%
Earn yld2.4%
EV/EBITDA28.3x
ROE·
Gross mgn77%
Net mgn20%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Ajanta Pharma es una empresa farmacéutica india especializada en la fabricación de medicamentos genéricos y productos sanitarios. Cotiza en la Bolsa de Bombay.